Novo Nordisk is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world’s best-selling drugs.
The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.
Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.
Novo is trying to win back market share from rival Eli Lilly & Co., pinning its comeback on new formulations of its top-selling medicines and a more direct-to-consumer approach.
A Wegovy pill introduced in January has had the strongest launch of any obesity drug to date, while Novo has also introduced a subscription program offering lower monthly prices for the drug.
Published On May 2, 2026 at 07:06 PM IST
Join the community of 2M+ industry professionals.
Subscribe to Newsletter to get latest insights & analysis in your inbox.
All about ETPharma industry right on your smartphone!
